Liquidia (NASDAQ:LQDA) Shares Break Below 200-Day Moving Average - What's Next?

Liquidia logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Liquidia shares fell below their 200-day moving average, trading at $54.43 versus the $55.06 average, after dipping to $53.97.
  • Analyst views are mixed, but the consensus rating is Moderate Buy with an average price target of $75.23; recent targets ranged from $40 to $77.
  • Quarterly revenue rose 314.9% year over year to $225.3 million, topping estimates, while earnings per share of -$2.64 missed the consensus estimate of $0.96.
  • MarketBeat previews the top five stocks to own by December 1st.

Liquidia Corporation (NASDAQ:LQDA - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $55.06 and traded as low as $53.97. Liquidia shares last traded at $54.43, with a volume of 1,690,881 shares trading hands.

Wall Street Analyst Weigh In

LQDA has been the topic of several analyst reports. Zacks Research raised shares of Liquidia from a "strong sell" rating to a "hold" rating in a research note on Thursday, November 12th. Raymond James Financial raised shares of Liquidia from an "outperform" rating to a "strong-buy" rating and boosted their price objective for the stock from $53.00 to $77.00 in a research note on Wednesday, November 11th. Wall Street Zen lowered shares of Liquidia from a "buy" rating to a "hold" rating in a report on Saturday, October 3rd. Wells Fargo & Company upped their target price on Liquidia from $33.00 to $40.00 and gave the stock an "equal weight" rating in a research note on Wednesday, November 11th. Finally, Jefferies Financial Group upped their target price on Liquidia from $55.00 to $62.00 and gave the company a "buy" rating in a report on Tuesday, November 10th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Liquidia has a consensus rating of "Moderate Buy" and an average target price of $75.23.

Get Our Latest Research Report on LQDA

Liquidia Price Performance

The company has a 50 day moving average price of $47.77 and a 200 day moving average price of $55.06. The company has a market capitalization of $4.90 billion, a P/E ratio of -44.25 and a beta of 0.40. The company has a current ratio of 1.02, a quick ratio of 0.96 and a debt-to-equity ratio of 0.63.

Liquidia (NASDAQ:LQDA - Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported ($2.64) earnings per share for the quarter, missing the consensus estimate of $0.96 by ($3.60). Liquidia had a positive return on equity of 264.65% and a negative net margin of 15.15%. The business had revenue of $225.30 million for the quarter, compared to the consensus estimate of $214.18 million. During the same quarter in the previous year, the company earned ($0.04) earnings per share. The firm's revenue for the quarter was up 314.9% on a year-over-year basis. On average, equities analysts predict that Liquidia Corporation will post 3.36 EPS for the current fiscal year.

Insider Activity

In related news, CFO Michael Kaseta sold 18,938 shares of Liquidia stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $539,354.24. Following the sale, the chief financial officer owned 340,148 shares of the company's stock, valued at approximately $9,687,415.04. This trade represents a 5.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Russell Schundler sold 13,692 shares of the stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $389,948.16. Following the transaction, the general counsel owned 602,841 shares in the company, valued at approximately $17,168,911.68. This represents a 2.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 358,232 shares of company stock valued at $10,599,228. Company insiders own 25.60% of the company's stock.

Hedge Funds Weigh In On Liquidia

A number of hedge funds have recently bought and sold shares of the business. Pinnacle Wealth Planning Services Inc. boosted its position in Liquidia by 26.2% during the third quarter. Pinnacle Wealth Planning Services Inc. now owns 1,557 shares of the company's stock worth $47,000 after acquiring an additional 323 shares during the last quarter. Sterling Capital Management LLC increased its stake in shares of Liquidia by 839.1% during the third quarter. Sterling Capital Management LLC now owns 2,329 shares of the company's stock worth $70,000 after acquiring an additional 2,081 shares during the period. Nisa Investment Advisors LLC grew its position in shares of Liquidia by 13.8% in the third quarter. Nisa Investment Advisors LLC now owns 2,634 shares of the company's stock valued at $80,000 after purchasing an additional 320 shares during the last quarter. Globeflex Capital L P acquired a new stake in Liquidia during the second quarter worth approximately $175,000. Finally, Nykredit A S acquired a new position in Liquidia in the second quarter valued at $177,000. Hedge funds and other institutional investors own 64.54% of the company's stock.

Liquidia Company Profile

(Get Free Report)

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing treatments for pulmonary hypertension and other serious diseases. Its work includes inhaled therapies designed to deliver medicines to the lungs. The company's marketed product, Yutrepia (treprostinil) inhalation powder, is approved in the United States for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Liquidia also has a pipeline of investigational therapies, including other formulations of treprostinil.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Liquidia Right Now?

Before you consider Liquidia, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liquidia wasn't on the list.

While Liquidia currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines